The incentives for orphan drug designation include: - Tax credits for clinical testing costs. - Seven years of market exclusivity after approval. - Fee waivers for marketing applications. - Grant funding for clinical trials. These incentives lower the financial barriers to developing drugs for rare cancers, encouraging pharmaceutical companies to invest in this essential research.
